Description

Mirtazapine Tablets IP 15 Mg – MITRACREST 15 Tablets

Description
MITRACREST 15 contains Mirtazapine Tablets IP 15 Mg , a noradrenergic and specific serotonergic antidepressant (NaSSA) indicated for the treatment of major depressive disorder (MDD). It blocks alpha-2 adrenergic autoreceptors and heteroreceptors, resulting in increased release of both norepinephrine and serotonin in the brain. Additionally, its antagonism at 5-HT2 and 5-HT3 receptors contributes to improved mood, reduced anxiety, and better sleep quality. The 15 mg strength is the standard recommended therapeutic starting dose in adults as per clinical guidelines, providing effective antidepressant activity with a favorable tolerability profile.

Key Points
NaSSA Mechanism — Dual enhancement of norepinephrine and serotonin without reuptake inhibition
Standard Adult Starting Dose — 15 mg is the recommended therapeutic initiation dose as per clinical guidelines
Titration Flexibility — Can be stepped up to 30 mg or 45 mg based on patient response and tolerability
Improves Sleep Quality — Strong sedative and anxiolytic properties beneficial in depression with insomnia
Reduces Anxiety — Effective in managing anxiety symptoms co-existing with depression
Better GI Tolerability — 5-HT3 antagonism reduces nausea and GI side effects common with SSRIs

Targeted Specialties
Psychiatry
Neurology
General Physician & Internal Medicine

Disclaimer:* To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.